On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Japan’s 1st Sakigake-Designated Oncolytic Virus Up for Advisory Panel Review on May 24
May 18, 2021
- AstraZeneca, Moderna COVID-19 Vaccines Up for Key Panel Review on May 20
May 17, 2021
- Japan, Pfizer Agree on 50 Million Extra Vaccine Doses by Sept-End
May 17, 2021
- Eisai’s EZH2 Inhibitor Up for PAFSC Review on May 28
May 17, 2021
- Daiichi Sankyo CEO Urges Rethink of Vaccine Approval System
May 17, 2021
- LDP Project Team Urges Overhaul of Unpredictable Pricing System: Proposal
May 14, 2021
- LDP Panels Call for Emergency Approval Process, Eyes Japan Made Vaccines
May 14, 2021
- No Serious Safety Concerns Detected for Comirnaty: MHLW Safety Panels
May 14, 2021
- 1st Oral SMA Med Risdiplam Up for PAFSC Review on May 26
May 14, 2021
- Pharma Groups Want Price Maintenance for Patented Meds, Payer Sees It “Natural” to Rectify Gap: Chuikyo
May 13, 2021
- Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain
May 13, 2021
- Operating Profit Rate for Cost-Based Method Updated to 15.5%: Chuikyo
May 13, 2021
- Novo’s Growth Hormone, Teijin’s Osteoporosis Med Skip May Listing
May 13, 2021
- May Listing OK’ed for Darzquro, Pemazyre, Vitrakvi, Kesimpta and More
May 12, 2021
- Ultomiris Faces 4.3% Price Cut under CEA Scheme
May 12, 2021
- Breyanzi to Join NHI List on May 19 at Post-CEA-Adjusted Kymriah Price
May 12, 2021
- Tecentriq, 3 I/O Rivals Face Quarterly Re-Pricing; Price Cuts Yet Again for Opdivo, Keytruda
May 11, 2021
- Kanmin Taiwa Public-Private Confab Set for May 17
May 11, 2021
- MHLW to Fund 7 Development Projects for COVID-19 Therapies
May 11, 2021
- Japan in Talks with 3 Vaccine Makers for Additional Supplies, Eyes 250 Million More Doses
May 10, 2021
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…